ArticleBritish journal of cancer2023
Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma.
Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03529175 (Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).British journal of cancer · 2026Trial
- Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2026Article
- Does neoadjuvant therapy reduce pancreatic fistula after pancreatoduodenectomy and distal pancreatectomy?-a systematic review and meta-analysis.Hepatobiliary surgery and nutrition · 2026Article
- The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2026Article
- To develop prognostic markers related to drug resistance in pancreatic cancer patients based on multiple machine learning methods.Annals of medicine and surgery (2012) · 2025Article
- Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysis.The journal of liquid biopsy · 2025Review
- The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in patients with newly diagnosed pancreatic cancer.Scientific reports · 2025Observational
- Identification of key hub genes in pancreatic ductal adenocarcinoma: an integrative bioinformatics study.Frontiers in bioinformatics · 2025Article
- Weighted gene co-expression network analysis reveals key stromal prognostic markers in pancreatic cancer.Scientific reports · 2024Article
- High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.Journal of translational medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundChemotherapy for metastatic pancreatic adenocarcinoma (PDAC) offers limited benefits, but survival outcomes vary. Reliable predictive response biomarkers to guide patient management are lacking.
methodsPatient performance status, tumour burden (determined by the presence or absence of liver metastases), plasma protein biomarkers (CA19-9, albumin, C-reactive protein and neutrophils) and circulating tumour DNA (ctDNA) were assessed in 146 patients with metastatic PDAC prior to starting either concomitant or sequential nab-paclitaxel + gemcitabine chemotherapy in the SIEGE randomised prospective clinical trial, as well as during the first 8 weeks of treatment. Correlations were made with objective response, death within 1 year and overall survival (OS).
resultsInitial poor patient performance status, presence of liver metastases and detectable
conclusionsReadily measurable patient variables can aid the prediction of outcomes from combination chemotherapy used to treat metastatic PDAC. The role of CLINICAL
trial registrationISRCTN71070888; ClinialTrials.gov (NCT03529175).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.